Prices are updated after-hours


Sort by: after hours percent change | delayed percent change | gain open | gain high | gain close | publishing date

tags : Phase 3    save search

Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
ALNY | $146.59 -0.62% 0.31% | twitter stocktwits trandingview |
Health Technology
| | O: 2.06% H: 0.0% C: 0.0%

cardiac results phase 3
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
CNCE | $4.57 6.03% 1.16% | twitter stocktwits trandingview |
Health Technology
| | O: 6.07% H: 8.26% C: -13.24%

ctp-543 for topline trial positive results phase 3
Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
BHVN | $144.01 0.15% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 0.25% H: 1.91% C: 0.92%

for trial phase 3
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
PYPD | $4.61 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 2.54% H: 4.77% C: -3.24%

trial enroll phase 3
VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone
Published: 2022-05-23 (Crawled : 08:00) - prnewswire.com
ASND | $95.07 4.37% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 4.07% H: 2.7% C: 1.55%

trial results growth hormone phase 3 topline
Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension
Published: 2022-05-23 (Crawled : 06:00) - globenewswire.com
JNJ | News | $182.12 -0.09% 0.1% | twitter stocktwits trandingview |
Health Technology
| | O: 1.57% H: 0.0% C: 0.0%

hypertension positive phase 3
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
Published: 2022-05-19 (Crawled : 16:20) - ir.radiuspharm.com
RDUS | News | $10.205 0.94% -0.4% | twitter stocktwits trandingview |
Health Technology
| | O: -2.67% H: 0.0% C: 0.0%

elacestrant trial publication group phase 3
Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol
Published: 2022-05-21 (Crawled : 12:20) - prnewswire.com
SNYNF | News | $104.5 | twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
SNY | News | $52.62 -1.5% -0.41% | twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
REGN | $602.68 -1.6% 0.15% | twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist
TEVJF | News | $8.35 | twitter stocktwits trandingview |
Health Technology
| Email alert Add to watchlist

evkeeza children cholesterol trial phase 3 rare
Menarini Group and Radius Health, Inc. announce publication of elacestrant pivotal Phase 3 EMERALD clinical trial data in the Journal of Clinical Oncology
Published: 2022-05-20 (Crawled : 08:00) - prnewswire.com
RDUS | News | $10.205 0.94% -0.4% | twitter stocktwits trandingview |
Health Technology
| | O: -2.67% H: 0.0% C: 0.0%

elacestrant trial publication group phase 3
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
Published: 2022-05-19 (Crawled : 00:00) - globenewswire.com
KRYS | $68.07 -0.66% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 3.63% H: 1.97% C: 1.39%

for biotech phase 3
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
Published: 2022-05-19 (Crawled : 12:00) - biospace.com/
OCUP | $2.02 6.32% 7.37% | twitter stocktwits trandingview |
Health Technology
| | O: -15.14% H: 13.51% C: 10.27%

nyxol for topline eye trial positive results phase 3
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI)  
Published: 2022-05-19 (Crawled : 12:00) - globenewswire.com
ZEAL | $13.955 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 18.8% H: 2.81% C: -0.79%

pharma trial positive results phase 3
Aldeyra Therapeutics Announces that Post-Hoc Analysis of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness
Published: 2022-05-18 (Crawled : 13:00) - biospace.com/
ALDX P | $3.875 5.3% -4.89% | twitter stocktwits trandingview |
Health Technology
| | O: 2.14% H: 0.0% C: -6.11%

for ocular trial therapeutics phase 3
IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma
Published: 2022-05-18 (Crawled : 12:20) - biospace.com/
IOBT | $5.1 5.59% -8.49% | twitter stocktwits trandingview |
| | O: -2.9% H: 3.0% C: -17.91%

io102 keytruda treatment melanoma biotech trial phase 3
Kamada Announces Expansion of Pivotal Phase 3 Clinical Trial of Inhaled AAT to Additional Six Clinical Sites Across Europe; and Positive Recommendation by DSMB to Continue the Trial Without Modification
Published: 2022-05-17 (Crawled : 18:00) - biospace.com/
KMDA | News | $4.61 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 1.68% H: 3.0% C: 2.07%

expansion six trial positive phase 3
Entasis Therapeutics Presents Data Highlights from Phase 3 ATTACK Trial at 2022 American Thoracic Society Annual Conference
Published: 2022-05-17 (Crawled : 17:00) - biospace.com/
ETTX | $2.2 -0.91% | twitter stocktwits trandingview |
Health Technology
| | O: 1.71% H: 1.69% C: -0.56%

conference trial therapeutics phase 3
aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
Published: 2022-05-16 (Crawled : 19:00) - biospace.com/
LIFE | $2.88 0.7% 1.4% | twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 5.23% C: 0.65%

atyr1923 pharma phase 3
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
Published: 2022-05-12 (Crawled : 19:00) - biospace.com/
SRRA | $54.955 0.08% 0.06% | twitter stocktwits trandingview |
Health Technology
| | O: -0.06% H: 0.15% C: 0.13%

presentation phase 3
Upadacitinib (RINVOQ®) Achieved Clinical Remission and Endoscopic Response at One Year in Phase 3 Maintenance Study in Patients with Crohn's Disease
Published: 2022-05-11 (Crawled : 13:00) - biospace.com/
ABBV | News | $153.14 0.53% 0.04% | twitter stocktwits trandingview |
Health Technology
| | O: 0.21% H: 0.0% C: 0.0%

rinvoq disease response one phase 3
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 11:00) - biospace.com/
VERU | $12.85 -2.73% 0.0% | twitter stocktwits trandingview |
Health Technology
| | O: 20.75% H: 0.0% C: 0.0%
LLY | News S | $327.27 0.51% 0.04% | twitter stocktwits trandingview |
Health Technology
| | O: -3.03% H: 0.0% C: 0.0%

covid-19 fda sabizabulin for authorization positive phase 3
Your saved searches
Save your searches and get alerts when important news are released.

Mentioned Today
ABBV | News | $153.14 0.53% 0.04% | twitter stocktwits trandingview |
Health Technology

BNPQF | News | $50.78 | twitter stocktwits trandingview |
Finance

BNPQY | News | $25.46 | twitter stocktwits trandingview |
Finance and Insurance

BNPZY | News | $ 0% | twitter stocktwits trandingview |
Finance and Insurance

CNXC | News | $147.67 1.63% -0.04% | twitter stocktwits trandingview |
Information

CNXCV | News | $2.27 0% | twitter stocktwits trandingview |
Commercial Services

DMYD | News | $16.21 0% | twitter stocktwits trandingview |
Finance

DMYT | News | $22.76 0% | twitter stocktwits trandingview |
Finance

DRE | News | $56.17 -2.23% 0.0% | twitter stocktwits trandingview |
Finance

EPZM | News | $1.47 54.09% 7.97% | twitter stocktwits trandingview |
Health Technology

FTRP | News | $0.81 1.25% 0.0% | twitter stocktwits trandingview |
Health Care and Social Assistan...

HR | News | $27.23 1.38% 0.0% | twitter stocktwits trandingview |
Finance

HTA | News | $27.7 -0.22% 0.0% | twitter stocktwits trandingview |
Finance

IONQ | News | $4.83 -5.48% 2.07% | twitter stocktwits trandingview |
Professional, Scientific, and T...

LLY | News 4 | $327.27 0.51% 0.04% | twitter stocktwits trandingview |
Health Technology

OMC | News | $64.75 0.23% 0.0% | twitter stocktwits trandingview |
Commercial Services

PACB | News | $5.3 -5.53% -1.78% | twitter stocktwits trandingview |
Health Technology

PLD | News | $120.21 -1.94% 0.54% | twitter stocktwits trandingview |
Finance

PSORF | News | $9.55 0% | twitter stocktwits trandingview |
Consumer Services

RDUS | News | $10.205 0.94% -0.4% | twitter stocktwits trandingview |
Health Technology

SNY | News | $52.62 -1.5% -0.41% | twitter stocktwits trandingview |
Health Technology

SNYNF | News | $104.5 | twitter stocktwits trandingview |
Health Technology

SREV | News | $1.45 -2.76% | twitter stocktwits trandingview |
Technology Services

TUP | News 4 | $7.16 1.42% 0.0% | twitter stocktwits trandingview |
Producer Manufacturing

USAK | News | $30.85 -0.48% -0.39% | twitter stocktwits trandingview |
Transportation

WWE | News | $61.0 0.63% 0.0% | twitter stocktwits trandingview |
Consumer Services

ZEN | News | $74.65 0.65% -0.07% | twitter stocktwits trandingview |
Technology Services